Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones

被引:0
|
作者
Zhang, Fan [1 ,2 ,3 ]
Li, Wenjian [1 ,4 ]
机构
[1] Xuzhou Med Univ, Changzhou Clin Coll, Changzhou, Peoples R China
[2] Changzhou Third Peoples Hosp, Dept Endocrinol, Changzhou, Peoples R China
[3] Changzhou Third Peoples Hosp, Dept Clin Nutr, Changzhou, Peoples R China
[4] Changzhou Third Peoples Hosp, Dept Urol, Changzhou, Peoples R China
来源
KIDNEY & BLOOD PRESSURE RESEARCH | 2025年 / 50卷 / 01期
关键词
Fatty liver index; Metabolic dysfunction-associated steatotic liver disease; Kidney stones; Risk factors; NHANES; BODY-MASS INDEX; NEPHROLITHIASIS; PATHOGENESIS; NAFLD;
D O I
10.1159/000543404
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Introduction: This study aimed to investigate the potential association between the fatty liver index (FLI), metabolic dysfunction-associated steatotic liver disease (MASLD), and the risk of kidney stones using large-scale population-based data. Methods: This study employed a cross-sectional design, utilizing data from the 2007 to 2018 National Health and Nutrition Examination Survey (NHANES) database. A total of 24,342 participants were enrolled in the study, and fatty liver status was assessed by calculating the FLI. MASLD was diagnosed by FLI in conjunction with cardiometabolic criteria. Data on the history of kidney stones were obtained by self-report. We employed logistic regression models to analyze the association between FLI, MASLD, and kidney stone risk and constructed multivariable adjustment models to control for potential confounders. Furthermore, we used restricted cubic spline curve models to investigate the dose-response relationship between FLI and kidney stone risk and conducted subgroup and interaction analyses. Results: The study's results indicate a strong correlation between increasing FLI quartiles and a notable rise in the prevalence of kidney stones. Specifically, the risk of developing kidney stones was 1.68 times higher among participants in the highest FLI quartile compared to those in the lowest. Furthermore, patients with MASLD exhibited a 1.35-fold increased risk of developing kidney stones compared to those with non-MASLD. Subgroup analyses demonstrated that the correlation between MASLD and kidney stone risk was consistent across multiple subgroups. However, a significant interaction was observed in the subgroups of smoking status, physical activity level, and hypertension (interaction p < 0.05). The restricted cubic spline analysis did not yield a statistically significant nonlinear association between FLI and kidney stone risk. However, the study did identify inflection point values for FLI. Conclusion: This study demonstrated an association between FLI and MASLD and the risk of kidney stones. This suggests that these conditions may be pivotal risk factors for kidney stones. Further investigation is required to elucidate these associations' underlying mechanisms and develop efficacious interventions to reduce the risk of kidney stones. Also, formulating personalized prevention and treatment strategies for different population subgroups is paramount.
引用
收藏
页码:115 / 130
页数:16
相关论文
共 50 条
  • [41] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
    Zheng, Haixiang
    Sechi, Leonardo Antonio
    Navarese, Eliano Pio
    Casu, Gavino
    Vidili, Gianpaolo
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [42] Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
    Vega, Luis
    Simian, Daniela
    Gajardo, Abraham I.
    Salinas, Marcelo
    Urra, Andrea
    Cattaneo, Maximo
    Pino, Rosario
    Roblero, Juan P.
    Urzua, Alvaro
    Rojas, Katherine
    Poniachik, Jaime
    ANNALS OF HEPATOLOGY, 2024, 29 (04)
  • [43] Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study
    Peng, Yu
    Wang, Peng
    Liu, Fubin
    Wang, Xixuan
    Si, Changyu
    Gong, Jianxiao
    Zhou, Huijun
    Gu, Jiale
    Qin, Ailing
    Song, Weijie
    Song, Fangfang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1940 - 1949
  • [44] Increased risk of cancers in metabolic dysfunction-associated steatotic liver disease and MetALD
    Park, Yewan
    Jung, Jooyi
    Kim, Gi-Ae
    JOURNAL OF HEPATOLOGY, 2024, 80 : S468 - S468
  • [45] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [46] Healthy Lifestyle and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of the Efficacy of Fatty Liver Regression
    Wang, Jingwei
    Zhao, Jinli
    Zhong, Yueyuan
    He, Chengyue
    Hu, Fen
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2025, 16 (02)
  • [47] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [48] From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
    Razzak, Iyiad Alabdul
    Noureddin, Mazen
    Trivedi, Hirsh D.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [49] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [50] Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
    Chen, Jiaxin
    Jian, Linge
    Guo, Yangkun
    Tang, Chengwei
    Huang, Zhiyin
    Gao, Jinhang
    ANTIOXIDANTS, 2024, 13 (06)